Uejima Chihiro, Saito Hiroaki, Tada Yoichiro, Tanio Akimitsu, Murakami Yuki, Yamamoto Manabu, Matsunaga Tomoyuki, Fukumoto Yoji, Tokuyasu Naruo, Takano Shuichi, Sakamoto Teruhisa, Honjo Soichiro, Fujiwara Yoshiyuki
Division of Gastrointestinal and Pediatric Surgery, Department of Surgery, School of Medicine, Faculty of Medicine, Tottori University, Yonago 683-8504, Japan.
Department of Surgery, Japanese Red Cross Tottori Hospital, Tottori 680-8517, Japan and.
Yonago Acta Med. 2021 May 20;64(2):176-183. doi: 10.33160/yam.2021.05.009. eCollection 2021 May.
The efficacy of adjuvant chemotherapy in stage II colorectal cancer (CRC) patients has not been clearly demonstrated. Therefore, identification of robust prognostic factors is crucial for the assessment of recurrence risk in stage II CRC and appropriate adjuvant treatment, in clinical practice.
We enrolled 135 colorectal adenocarcinoma patients who underwent proctocolectomies and had histologically diagnosed stage II CRC.
Receiver operating characteristic (ROC) analysis, to evaluate the predictive ability of certain serum factors for CRC recurrence, indicated that the prognostic nutritional indicator (PNI), followed by serum carcinoembryonic antigen (CEA) level, were the strongest predictive metrics. Based on cutoff values from ROC analyses, patients were divided as follows; CEA (≥ 4.55 ng/mL), CEA (< 4.55 ng/mL), PNI (≥ 47.72), and PNI (< 47.72). The recurrence rates of patients with CEA and PNI, CEA and PNI, CEA and PNI, and CEA and PNI were 34.3%, 0%, 6.8%, and 2.6%, respectively (a significant difference at < 0.0001). Logistic regression analysis revealed that the combination of serum CEA level and PNI was an independent predictive indicator of tumor recurrence after operation in stage II CRC patients. The 5-year disease specific survival rates of patients with CEAPNI, CEAPNI, CEAPNI, CEAPNI were 100%, 100%, 97.4%, and 77.5%, respectively ( < 0.0001).
The combination of CEA and PNI was useful in predicting postoperative recurrence in stage II CRC patients.
辅助化疗在II期结直肠癌(CRC)患者中的疗效尚未得到明确证实。因此,在临床实践中,识别可靠的预后因素对于评估II期CRC的复发风险和适当的辅助治疗至关重要。
我们纳入了135例行直肠结肠切除术且经组织学诊断为II期CRC的结直肠腺癌患者。
通过接受者操作特征(ROC)分析来评估某些血清因子对CRC复发的预测能力,结果表明预后营养指标(PNI),其次是血清癌胚抗原(CEA)水平,是最强的预测指标。根据ROC分析的临界值,将患者分为以下几组:CEA(≥4.55 ng/mL)、CEA(<4.55 ng/mL)、PNI(≥47.72)和PNI(<47.72)。CEA和PNI、CEA和PNI、CEA和PNI以及CEA和PNI患者的复发率分别为34.3%、0%、6.8%和2.6%(<0.0001时有显著差异)。逻辑回归分析显示,血清CEA水平和PNI的组合是II期CRC患者术后肿瘤复发的独立预测指标。CEAPNI、CEAPNI、CEAPNI、CEAPNI患者的5年疾病特异性生存率分别为100%、100%、97.4%和77.5%(<0.0001)。
CEA和PNI的组合有助于预测II期CRC患者的术后复发。